KR101822486B1 - Drug releasing type hybrid stent - Google Patents

Abstract

The present invention relates to a drug releasing type fusion stent, wherein a metal wire of a shape memory alloy material forms a plurality of cells by intersection of wires, and is provided with a first wire Structure; And at least one second wire structure provided on the outer circumferential surface of the metal wire forming the first wire structure as the biodegradable wire is wound and wound from one end of the first wire structure to the other end of the first wire structure, Wherein the biodegradable wire forming the second wire structure comprises: a wire body made of a biodegradable polymer; And a coating layer formed on the outer circumferential surface of the wire body by coating a mixture of the biodegradable polymer and the drug.

Description

[0001] DRUG RELEASING TYPE HYBRID STENT [0002]

The present invention relates to a drug release type fusion stent.

The stent is placed so as to lie in the same lumen as the lesion site where the stenosis usually occurs, and then the structural extension at the site of installation is achieved through the shape memory of the metal wire or by the aid of a separate extension member, Maintaining the long-term and restricting the diameter of the lumen narrowed by the stenosis and ensuring the movement path for smoothly moving the mass to the expanded lumen.

Such a stent should be designed such that the degree of an extended structural response to the structure of the lumen to be installed, the ability to prevent departure from the mounting position, and the ability to minimize various side effects other than the ability to stay in the lumen for long periods and recover the lumen diameter The development direction of the stent is variously attempted such as the structural change of the whole stent, the manufacturing method change of the stent wire, the addition of the stent structure or the design change. have.

In addition to using the stent, the diameter of the narrowed lumen narrowed by the stenosis is restored and restored. In addition to the metal wire layer forming the stent basic framework, other medicines for therapeutic purposes can be provided on the lesion site causing the stenosis. Techniques for further designing a separate wire layer provided by biodegradable or biocompatible materials have also recently been developed.

In this regard, a second member stent structure layer capable of releasing a drug is additionally designed to additionally design a metal-wire-based first member stent structure layer for restoring the diameter of the lumen of the entire stent structure. A prior art document discloses a drug coating for a drug release-controlled biodegradable stent, a preparation method thereof, and a biodegradable stent coated with the coating solution, and a preparation method thereof (hereinafter referred to as " Technology ").

However, stents of various structures for the purpose of releasing conventional drugs, including conventional techniques, have a similar or identical shape to a metal wire-based member constituting a stent basic frame, And a stent cell (Cell), which is a little smaller than the stent cell (Cell), can be provided. Therefore, even if the drug is released, the drug can not be effectively applied to the lesion site, There is a problem that the efficacy of therapeutic treatment through substantial drug release is limited to a low level.

In addition, taking into account the types of lesions and the state of the lesions that caused stenosis at the stent placement site, the release of various drugs may not be sequentially discharged due to mutual time differences, There is a problem in that a plurality of drugs are released in a batch to fail to provide an effect of treatment through an effective drug.

SUMMARY OF THE INVENTION The present invention has been made in order to overcome the above problems, and it is an object of the present invention to effectively and effectively release a majority of a drug to a lesion site where a stent is installed and to perform effective release of a single drug, The present invention also provides a stent in which the sequential release and action of the drug can be effectively performed.

In order to achieve the above object, a drug releasable fusion stent according to the present invention comprises a metal wire of a shape memory alloy material formed by crossing wires to form a plurality of cells, A first wire structure; And at least one second wire structure provided on the outer circumferential surface of the metal wire forming the first wire structure as the biodegradable wire is wound and wound from one end of the first wire structure to the other end of the first wire structure, Wherein the biodegradable wire forming the second wire structure comprises: a wire body including a biodegradable polymer; And a first coating layer formed on the outer surface of the wire body by coating a mixture of the biodegradable polymer and the drug.

Here, the wire body is made of a first biodegradable polymer, and the first coating layer is provided through a coating process on an outer circumferential surface of the wire body using a mixture of a second biodegradable polymer and a drug, and the first biodegradable polymer, The decomposition cycle of the wire body and the first coating layer may be different from each other as the second biodegradable polymer differs in at least one of the type and composition ratio of the biodegradable polymer.

The biodegradable wire forming the second wire structure may further include a second coating layer on which a mixture of the biodegradable polymer and the drug is laminated on the outer circumferential surface of the first coating layer.

Here, the first coating layer is formed through a coating process on the outer surface of the wire body using a mixture of the second biodegradable polymer and the first drug, and the second coating layer is formed using a mixture of the third biodegradable polymer and the second drug The first biodegradable polymer and the third biodegradable polymer are provided through a lamination coating process on the outer circumferential surface of the first coating layer, and the second biodegradable polymer and the third biodegradable polymer are different from each other in at least one of the types and composition ratios of the biodegradable polymer, And the decomposition period of the second coating layer are different from each other, and the first drug and the second drug are different from each other.

And wherein the fusion stent further comprises a plurality of radiopacity indicators disposed in a plurality of regions on the first wire structure for securing visibility of the fused stent in a body, At least two radiopacity indicators provided on both ends of the fusion stent are installed in such a manner that both ends of the second wire structure are fixedly connected to the outer circumferential surface of the first wire structure.

The second wire structure may be formed such that a shape in which the biodegradable wire is wound and moved on the outer circumferential surface of the metal wire forming the first wire structure extends from one end of the first wire structure to the other end of the first wire structure, As shown in FIG.

The helical movement form formed by the second wire structure on the first wire structure is formed in the longitudinal direction of the fusable stent from the movement start position corresponding to one end of the second wire structure At least one or more number of movement turns indicating a spiral movement to a movement position having a virtual circumferential dividing line are formed.

The drug-releasing fusion stent according to the present invention is a drug-

First, it is possible to restore the diameter of the lumen where the stenosis is caused by the lesion site through the first wire structure of the stent, and at the same time, to discharge the drug through the second wire structure and to provide therapeutic effect on the lesion site through the second wire structure .

Second, the second wire structure is wound on the outer circumferential surface of the metal wire from one end to the other end of the first wire structure, and has a helical movement form as a whole, thereby discharging the drug discharged from the second wire structure and applying the drug to the lesion site This functional loss can be minimized and effective.

Third, the structure of the second wire structure is provided with a multi-layer lamination coating method according to the embodiment, and the discharge cycle of the layered drug is set differently according to the kind or composition ratio of the biodegradable polymer and the drug, It is possible to effectively perform a plurality of drug treatments best suited for the time period.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a perspective view showing a drug release type fusion stent structure according to the present invention. FIG.
FIG. 2 is a front view and an enlarged view of a drug releasing type fusion stent structure according to the present invention.
FIG. 3 is a reference view for explaining a difference in drug release pattern through biodegradation between a conventional biodegradable stent and a drug releasing type fusion stent according to the present invention.
4 is a cross-sectional view illustrating a cross-sectional structure of a first wire structure and a second wire structure of the drug release type fusion stent according to the first embodiment of the present invention.
5 is a cross-sectional view illustrating a cross-sectional structure of a first wire structure and a second wire structure of the drug release type fusion stent according to the second embodiment of the present invention.
FIG. 6 is a cross-sectional view illustrating a cross-sectional structure of a first wire structure and a second wire structure of the drug release-type fusion stent of the present invention according to the third embodiment.

The preferred embodiments of the present invention will be described in more detail with reference to the accompanying drawings, in which the technical parts already known will be omitted or compressed for the sake of brevity.

<Drug release type Convergence Stent  Description of Structure and Description>

1 to 3, a drug releasing type fusion stent 100 (hereinafter referred to as "fusion stent") of the present invention comprises a first wire structure 110; A second wire structure 120; And a radiation-impermeable indicator 130.

The first wire structure 110 is formed by binding a metal wire 110W, which is a shape memory alloy, as shown in FIG. 1 on a jig through bending up and down to form a hollow structure having a plurality of cells C, Means a portion forming a basic skeleton in a stent wire structure provided in a cylindrical shape.

Here, the first wire structure 110 is formed of a shape memory alloy, which is woven on a jig and has a specific structure, and then the shape is memorized by a heat treatment process.

In the first wire structure 110, the diameter of the lumen is expanded by self-expanding based on the shape memory at the stent installation site where the lumen is stuck due to the lesion, and it is maintained in the stent installation period .

This is the same even after the biodegradation of the second wire structure 120 as described below is entirely performed. When the biodegradation of the second wire structure 120 is entirely performed, the first wire structure 110 increases the extent of the diameter of the lumen You can spread it.

Accordingly, the first wire structure 110 may continuously expand as the biodegradation of the second wire structure 120 progresses, thereby gradually increasing the diameter recovery level of the lumen.

In some cases, the first wire structure 110 may be provided with a portion 111 that forms a support bar through a separate winding-type weaving movement in the course of the weaving movement of the metal wire 110W through the vertical bending of the metal wire 110W have,

2, the second wire structure 120 includes a biodegradable wire 120W on the outer circumferential surface of the metal wire 110W forming the first wire structure 110, At least one structure may be provided as a structure that is provided by winding from the first wire structure 110 (the longitudinal direction reference) to the other end (the longitudinal direction reference) of the first wire structure 110.

The biodegradable wire 120W constituting the second wire structure 120 includes a biodegradable polymer M on the outer surface of the wire body 121 using the wire body 121 including the biodegradable polymer M as a basic wire framework, M) and a drug (D) is coated and provided on the first coating layer 122.

Here, the biodegradable polymer (M) may be at least one selected from the group consisting of polyethylene, polyester, polypropylene, polyvinyl chloride, expanded poly (ethylene terephthalate) (ePTFE), polyethylene naphthalate, polystyrene naphthalate, polytrimethylene naphthalate, Fluorinated ethylene propylene such as naphthalate, polytetrafluoroethylene, polyurethane, polyurea, silicone, polyamide, polyimide, polycarbonate, polyaldehyde, polyetheretherketone, natural rubber, polyether, fluorinated ethylene propylene , Fully or partially halogenated polyethers such as polyvinyl acetate, polystyrene, poly (ethylene terephthalate), naphthalene, dicarboxylate derivatives, polyvinyl alcohol, polyethylene glycol, polylactide, polyglycolide, polyethylene oxide, poly Dioxanone, polycaprolactone One of or a combination of two or more of the following: polyvinylpyrrolidone, polyvinylpyrrolidone, polyvinylpyrrolidone, polyvinylpyrrolidone, polyvinylpyrrolidone, polyvinylpyrrolidone, polyvinylpyrrolidone, polyvinylpyrrolidone, As shown in FIG.

Specifically, the biodegradable polymer (M) may be a polyester-based copolymer, a styrene-butadiene copolymer, a silicone urethane copolymer, or the like.

The biodegradable polymer (M) may be selected from the group consisting of poly (L-lactide) (PLLA), poly (L-lactide) (PLA), poly (glycolide) (PLA / PGA), poly (L-lactide-co-glycolide) (PLLA / PGA) (PGA / PTMC), polydioxanone (PDS), polycaprolactone (PCL), polyhydroxybutyrate (PHBT), poly (phosphazene) poly (D, L-lactide- co-caprolactone) PLA / PCL, glycolide-co-caprolactone (PGA / PCL), poly (phosphate ester) and copolymers thereof.

Next, the drug (D) may be administered in combination with an anticancer agent (paclitaxel, doxorubicin, gemcitabin, 5-FU, abraxane, vinblastin, sorafenib, cetuximab, imatinib, gefitinib, erlotinib, sunitinib, trastuzumab, All antibiotics such as cefotaxime, vancomycin, tetracycline, beta-lactam antibiotics, polyamicin, sulfamate, pyrimethamine, rifampin, quinolone and aminoglycoside; immunosuppressants such as sirolimus, zotarolimus and everolimus; limus family), anti-platelet (cilostazol), or a combination thereof.

In addition, the drug (D) is not limited thereto and may be variously provided. Examples thereof include adrenergic agonists, corticosteroids, adrenocortic inhibitors, alcohol inhibitors, aldosterone antagonists, amino acids and proteins, ammonia detoxicants, Anesthetic agent, an anti-allergic agent, an anti-adrenergic agent, an anti-adrenergic agent, an anti-adrenergic agent, an anti-inflammatory agent, An antihypertensive agent, an anticholinergic agent, an antihypertensive agent, an antihypertensive agent, an antihypertensive agent, an antihypertensive agent, an antihypertensive agent, an antihypertensive agent, anticoccidal agents, anticonvulsants, antidepressants, antidepressants An antihypertensive agent, an antihypertensive agent, an anti-epileptic agent, an anti-epileptic agent, an anti-epileptic agent, an anti-epileptic agent, an anti-fibrotic agent, an antifibrinolytic agent, Anti-hypertensives, antihypertensives, antihypertensive agents, antimicrobial agents, anti-migraine agents, cell division inhibitors, antifungal agents, anti-cancer agents, anti-cancer agents Antiproliferative agents, antiparkinsonian agents, anti-cystic agents, antiproliferative agents, anti-prostatic hypertrophy drugs, antibiotics, anti-allergic agents, anti-psoriasis agents, anti- Antipsychotic agent, anti-rheumatic agent, antidiarrheal agent, anti-seborrhoeic agent, spasmodic agent, anti-thrombotic agent, cough suppressant agent, anti-ulcer agent, A cardiovascular agent, a cardiovascular agent, a laryngeal secretagogue agent, a cholinergic agent, a cholinergic agent, a cholinesterase inactivation agent, an antiinflammatory agent, an antiinflammatory agent, an antiinflammatory agent, an antiviral agent, a bone resorption inhibitor, a bronchodilator, a carbonic anhydrase inhibitor, The present invention relates to a method of stimulating the production of a coccidiosis agent, a sedative agent, a diagnostic aid program, a diuretic agent, a dopaminergic agent, an ectoparasiticide, a vomitogen, an enzyme inhibitor, an estrogenic hormone, a fibrous agent, a free oxygen radical scavenger, , Hemostatic agent, histamine H2 receptor antagonist, hormone, hypocholesterolemic agent, hypoglycemic agent, hypotonic agent, hypotensive agent, hmgcoa reductase inhibitor, cotton competency agent, immunomodulator, keratolytic agent, LHRH Antagonist, luteolin agent, mucopolysaccharide hydrolysable, A nerve blocker, a neuroprotective agent, an NMDA antagonist, a non-hormonal sterol derivative, a uterine contractile agent, a plasminogen activator, or a combination thereof .

The second wire structure 120 (120) using the biodegradable polymer (M) and the drug (D) as described above may be used in accordance with the purpose of use (treatment purpose considering the shape, ) May be provided in various embodiments.

The biodegradable wire 120W constituting the second wire structure 120 of the convergent stent 100 according to the first embodiment is formed by inserting the wire body 121 into the first biodegradable polymer 120 M1), and when the first coating layer 122 is of a different kind or the same kind as the first biodegradable polymer (M1), a mixture of the second biodegradable polymer (M2) and the first drug D1 The wire body 121 may be provided with a coating process.

In this case, the first biodegradable polymer (M1) and the second biodegradable polymer (M2) may be selected from among the candidate groups of the biodegradable polymer (M) described above (which may be selected from among various known biodegradable polymers The types of the biodegradable polymer (M) are different from each other or the biodegradable polymer (M) is composed of the same type of biodegradable polymer (M), and the composition ratio of the biodegradable polymer The decomposition periods of the wire body 121 and the first coating layer 122 such as the time at which the biodegradation starts, the rate at which the biodegradation proceeds, and the time at which the biodegradation is completed are different from each other Respectively.

In this way, the fusion stent 100 according to the first embodiment is configured such that the first drug D1 of the first coating layer 122 is embedded in the second biodegradable polymer 122 in a state where the wire body 121 is not biodegraded, Is released through the biodegradation of the cell M2 to slowly move along the outer circumferential surface of the wire body 121 and the metal wire 110W constituting the first wire structure 110, It is possible to minimize the amount of the tumor that is discharged without being affected and to effectively act on the lesion site.

5, the biodegradable wire 120W 'constituting the second wire structure 120' of the fusion-type stent 100 'according to the second embodiment includes the first biodegradable polymer M1, And the first biodegradable polymer M2 and the first drug D1 are coated on the outer circumferential surface of the wire body 121 'using a wire body 121' 1 coating layer 122 'and a mixture of the third biodegradable polymer M3 and the second drug D2 on the outer circumferential surface of the first coating layer 122' And may further include a coating layer 123.

In this case, the first biodegradable polymer (M1), the second biodegradable polymer (M2), and the third biodegradable polymer (M3) are selected from the candidate groups of the biodegradable polymer (M) And the biodegradable polymer (M) in the whole composition is composed of the biodegradable polymer (M) of the same type or the same type of the biodegradable polymer (M) The time at which biodegradation of the wire body 121 ', the first coating layer 122' and the second coating layer 123 is started as the composition ratio of the biodegradable polymer M is different from that of the biodegradable polymer M, And the time point at which the biodegradation is completed are set to be different from each other.

Accordingly, the fusion-type stent 100 'according to the second embodiment is configured such that the wire body 121' and the first coating layer 122 'are not biodegraded so that the second coating layer 123' The second drug D2 of the third biodegradable polymer M3 is released through the biodegradation of the third biodegradable polymer M3 to move slowly along the outer circumferential surface of the metal wire 110W constituting the first coating layer 122 'and the first wire structure 110 , The amount of the drug released into the stent 100 through the cell C without drug action is minimized and can be effectively applied to lesions.

Thereafter, the fusable stent 100 'according to the second embodiment is configured such that the first drug D1 of the first coating layer 122' is formed in a state in which the wire body 121 'is not biodegraded, Is released through the biodegradation of the second biodegradable polymer M2 and moves slowly along the outer circumferential surface of the metal wire 110W constituting the wire body 121 'and the first wire structure 110, The amount of the drug that is discharged without drug action into the blood vessel 100 is minimized and can be effectively applied to the lesion site.

Accordingly, the fusion stent 100 'according to the second embodiment can sequentially provide a plurality of drugs to the lesion site, and further, on the basis of this method, the multilayered multilayer coating 100' on the outer circumferential surface of the wire body 121 ' A plurality of drugs are successively provided to the lesion site so that the drug can be developed into a form capable of continuously providing the effects of various drugs with mutual time differences.

6, the biodegradable wire 120W '' constituting the second wire structure 120 '' of the fusion stent 100 '' according to the third embodiment is different from the first biodegradable polymer 120 ' The second biodegradable polymer M2 and the second biodegradable polymer M2 'are formed on the outer circumferential surface of the wire body 121' 'using the wire body 121' 'including the drug for the body D0, And a first coating layer 122 '' on which a mixture of the first drug D1 and the second drug D1 is coated.

In this case, the first biodegradable polymer (M1) and the second biodegradable polymer (M2) may be selected from among the candidate groups of the biodegradable polymer (M) described above (which may be selected from among various known biodegradable polymers The types of the biodegradable polymer (M) are different from each other or the biodegradable polymer (M) is composed of the same type of biodegradable polymer (M), and the composition ratio of the biodegradable polymer The decomposition period such as the time at which the biodegradation of the wire body 121 '' and the first coating layer 122 '' starts, the rate at which biodegradation proceeds, and the time at which the biodegradation is completed, Are set different from each other.

In this way, the fusion stent 100 '' according to the third embodiment is configured such that the wire body 121 '' is primarily biodegraded and the skeleton of the first body of the first coating 122 ' (D1) is released through the biodegradation of the second biodegradable polymer (M2) to move slowly along the outer circumferential surface of the metal wire (110W) constituting the wire body (121 '') and the first wire structure (110) The amount of the stent 100 discharged through the stent 100 without the drug action is minimized and can be effectively applied to the lesion site.

Thereafter, the convergent stent 100 '' according to the third embodiment is secondarily discharged through the biodegradation of the first biodegradable polymer (M1) for the body of the wire body 121 '' The first wire structure 110 moves slowly along the outer circumferential surface of the metal wire 110W and minimizes the amount of the drug released into the stent 100 through the cell C, have.

Accordingly, the fusion body stent 100 '' according to the third embodiment includes the wire body 121 '' as well as the drug, and sequentially provides a plurality of drugs to the lesion site as in the second embodiment described above And the structural features of the convergent stent 100 &quot; according to the third embodiment are also applicable to the second embodiment described above.

2 and 3 (b), the second wire structure 120, which can be provided in various structures as described above, is formed on the outer circumferential surface of the metal wire 110W forming the first wire structure 110, It is preferable that the wire 120W is wound and moved so as to form a spiral from one end of the first wire structure 110 to the other end of the first wire structure 110.

3 (b), the biodegradable wire 120W is wound on the outer circumferential surface of the metal wire 110W forming the first wire structure 110, The first member 11 based on the metal wire and the second member 12 based on the biodegradable polymer both have a hollow cylindrical stent framework as shown in Fig. 3 (a) So as to form a complete stent 10, in order to solve various problems.

The conventional stent 10 is a biodegradable polymer-based biodegradable polymer-based second member 12 provided with a first member 11 based on a metal wire and a second member 12 based on a biodegradable polymer as shown in FIG. The drug released at the time when the member 12 is biodegraded and released is easily introduced into the cell 13 provided in the stent structure or discharged outward in the stent longitudinal direction so that the action of the drug can not be effectively performed.

Accordingly, the fusion stent 100 of the present invention has a structure in which the drug discharged from the biodegradable wire 120W forming the second wire structure 120 is inserted into the first wire structure 110 wound with the biodegradable wire 120W So that the drug can act on the lesion effectively without loss of the release dose.

2, a helical movement form formed on the first wire structure 110 is a movement start position P1 corresponding to one end of the second wire structure 120. The helical movement form formed by the second wire structure 120 on the first wire structure 110, (T) indicating a spiral movement from the movement start position to the movement position (P2) in which the imaginary circumferential dividing line (L) is formed in the longitudinal direction of the fusion stent (100) Is formed.

This is because when the biodegradable wire 120W is wound on the outer circumferential surface of the metal wire 110W forming the first wire structure 110 as a whole, The second wire structure 120 performing the substantial drug releasing function is wound around the fusing stent 100 in the circumferential direction from one end of the first wire structure 110 to the other end of the first wire structure 110 So that the drug is delivered to all the surfaces contacting the outer circumferential surface of the fusable stent 100 over the reference normal direction.

Thus, regardless of the configuration and phase on the stenotic region of the fusable stent 100, at least one drug released from the second wire structure 120 will eventually migrate over the constriction to be treated.

As shown in FIG. 2, the fusion-type stent 100 includes a plurality of radiation-impermeable indicators (not shown) installed in a plurality of regions on the first wire structure 110 for ensuring the visibility of the fusible stent 100 installed in the body 130).

Herein, the plurality of radiopaque markers 130 is a kind of marker for confirming the internal position of the fusion stent 100 from the outside through inspection using X-ray or the like radiation, and functions as a position indicator Function. Some of which serve as a connective radiopacity indicator 130 '.

In other words, at least two radiation-impermeable indicators 130 'provided on both end sides of the fusion stent 100 among the plurality of radiation-impermeable indicators 130 are formed as shown in the enlarged view of FIG. The two-wire structure 120 is installed in such a manner that both ends of the two-wire structure 120 are fixedly connected to the outer circumferential surface of the first wire structure 110 and functions as a position indicator and a connection between the second wire structure 120 and the first wire structure 110 And also provides a function of fixing the position through the same.

In addition, the fusion stent 100 may additionally include a separate coating layer (not shown) or a coating layer (not shown) covering the inside or the outside of the first wire structure 110 according to the embodiment.

Here, the coating film may be formed of a material such as polyurethane, silicone urethane copolymer, silicone, polyamide, polyester, fluorine resin, polytetrafluoroethylene, polyvinyl alcohol, polyethylene glycol, polylactide, polyglycolide, polylactide copolymer, But are not limited to, polyethylene oxide, polydioxanone, polycaprolactone, polyphosphazene, polyanhydride, polyamino acid, cellulose acetate butyrate, cellulose triacetate, polyacrylate, polyacrylamide, polyurethane, polysiloxane, But is not necessarily limited to, a film formed by spraying using a coating solution that can be selected from the group consisting of polyvinyl pyrrolidone, dextrone, and copolymers thereof.

 The coating can also be selected from among Teflon, silicone, Polytetrafluoroethylene, polyurethane, polyester, polypropylene, polyethylene, polyolefin, HDPE (High Density Polyethylene), and expanded-Polytetrafluoroethylene (ePTFE) Can be selected within the range of known materials used for coating without limitation.

The embodiments disclosed in the present invention are not intended to limit the scope of the present invention but to limit the scope of the technical idea of the present invention. The scope of protection is to be construed in accordance with the following claims, and all technical ideas within the scope of equivalents thereof should be construed as being included in the scope of the present invention.

100, 100 &apos;, 100 &quot;: drug-releasing fusion stent
110: First word structure
110W: metal wire
120, 120 ', 120'': a second wire structure
120 W, 120 W ', 120 W'': Biodegradable wire
121, 121 ', 121'': wire body
122, 122 ', 122'': first coating layer
123: Second coating layer
130: Radiopaque indicator
130 ': Radiotransmittable indicator

Claims (7)

A first wire structure formed of metal wires of a shape memory alloy material by being interwoven with each other to form a plurality of cells by intersection of wires and having a hollow cylindrical shape; And
At least one second wire structure provided on the outer circumferential surface of the metal wire forming the first wire structure as the biodegradable wire is wound and wound from one end of the first wire structure to the other end of the first wire structure; / RTI &gt;
Wherein the biodegradable wire forming the second wire structure comprises:
A wire body comprising a biodegradable polymer; And
And a first coating layer formed on the outer circumferential surface of the wire body and coated with a mixture of a biodegradable polymer and a drug,
Drug release type fusion stent.
The method according to claim 1,
Wherein the wire body is made of a first biodegradable polymer and the first coating layer is provided through a coating process on an outer peripheral surface of the wire body using a mixture of a second biodegradable polymer and a drug,
Wherein the first biodegradable polymer and the second biodegradable polymer have different decomposition periods of the wire body and the first coating layer, respectively, as at least one of the types and composition ratios of the biodegradable polymer are different from each other
Drug release type fusion stent.
The method according to claim 1,
Wherein the biodegradable wire forming the second wire structure comprises:
And a second coating layer formed on the outer circumferential surface of the first coating layer and provided with a mixture of the biodegradable polymer and the drug mixed and laminated thereon
Drug release type fusion stent.
The method of claim 3,
Wherein the first coating layer is formed through a coating process on the outer surface of the wire body using the mixture of the second biodegradable polymer and the first drug and the second coating layer is formed on the outer surface of the wire body using the mixture of the second biodegradable polymer and the first drug, 1 coating layer on the outer circumferential surface,
The second biodegradable polymer and the third biodegradable polymer have different decomposition cycles of the first coating layer and the second coating layer as the at least one of the type and composition ratio of the biodegradable polymer is different, Characterized in that the first drug and the second drug are provided in mutually different classes
Drug release type fusion stent.
The method according to claim 1,
The fusable stent may be a stent,
And a plurality of radiopacity indicators mounted on a plurality of regions on the first wire structure for securing visibility of the fused stent installed in the body,
Wherein at least two radiopacity indicators provided on both ends of the fusion stent among the plurality of radiopacity indicators are configured to fix both end portions of the second wire structure on the outer circumferential surface of the first wire structure Characterized in that it is installed
Drug release type fusion stent.
The method according to claim 1,
The second wire structure may be formed such that a shape in which the biodegradable wire is wound and moved on the outer circumferential surface of the metal wire forming the first wire structure forms a spiral from one end of the first wire structure to the other end of the first wire structure And is provided in a moved form
Drug release type fusion stent.
The method according to claim 6,
Wherein the helical movement form formed by the second wire structure on the first wire structure is a virtual helical shape formed from the movement start position corresponding to one end of the second wire structure to the movement start position and the longitudinal direction of the convergent stent And at least one number of movement turns indicating a spiral movement to a movement position in which the circumferential division line is made to be the same.
Drug release type fusion stent.

Images